Image source: © Timonschneider | Megapixl.com
Highlights
- CSL is an ASX-listed firm which deals in pharmaceutical and diagnostic products, cell culture media and human plasma fractions
- CSL’s revenue in 1HFY24 jumped 12% to USD 8,053 million
- The Vanguard Group, Inc. has the highest stake in CSL with a shareholding of nearly 4.99%
CSL Limited (ASX: CSL) is involved in researching, developing, manufacturing, marketing, and distributing biopharmaceutical products and vaccines. It provides innovative life-saving medications across 100 countries.
In the first half of the financial year 2024 (1HFY24), revenue of CSL increased by 12% YoY to USD 8,053 million, EBITDA jumped 21% YoY to USD 3,042 million and NPAT grew by 17% YoY to USD 1,901 million.
Performance during the six months ended 31 December 2023 was underpinned by portfolio growth of CSL Behring, which registered 23% increase in sales of immunoglobulin products. Driven by international plasma supply, and increase in patient demand, positive performance was witnessed across all geographical regions.

Top 10 shareholders of CSL
The top 10 shareholders of CSL have around 19.75% shareholding in the company, while the top four have nearly 13.53% shareholding. The Vanguard Group, Inc. and State Street Global Advisors Australia Ltd. have highest stake in the company with a shareholding of ~4.99% and ~4.0%, respectively.
Recent business update
Through an ASX update dated 8 April 2024, the company posted an update about the publications of the secondary analyses and primary data as presented on AEGIS II Trial Data to the American College of Cardiology. CSL is focused on data assessment and there are no intent for a regulatory filing in the near term.
Outlook
In FY24, the company expects to register around 9-11% increase in revenue in constant currency and 13-17% rise in underlying NPATA to around USD 2.9 – 3.0 billion at constant currency.
For CSL Behring business segment, continued patient demand for Ig is expected in core indication and growth for HEMGENIX is expected in the second half, while continuing yield and plasma initiatives.
Share performance of CSL
CSL shares closed 1.17% lower at AUD 283.37 apiece on 10 April. In the past one year, CSL’s share price has decreased by 6.0%, and in the past three months, it has dropped by 2.0%.
The 52-week high of CSL is AUD 312.99, recorded on 6 June 2023, while the 52-week low is AUD 228.65, recorded on 30 October 2023.

CSL Daily Technical Chart, Source: REFINITIV
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 10 April 2024. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer:
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.